AlzeCure Pharma is thrilled to announce that it has successfully raised 2,500,000 SEK in its latest funding round, marking another significant milestone in its ongoing mission to transform treatment options for Alzheimer’s disease and pain. As a pioneering Swedish pharmaceutical company listed on Nasdaq First North Premier Growth Market, AlzeCure Pharma is committed to advancing innovative drug research through its two major platforms: NeuroRestore and Alzstatin. The NeuroRestore platform focuses on developing symptom-relieving drug candidates that aim to improve the quality of life for patients, while the Alzstatin platform is dedicated to creating disease modifying and preventive therapeutics. This diversified portfolio not only targets Alzheimer’s but also opens avenues for addressing other central nervous system disorders such as cognitive dysfunctions in traumatic brain injury (TBI), sleep apnea, and Parkinson’s disease.
The secured funding will be strategically allocated to bolster research and development efforts across the five promising drug candidates currently in the pipeline. In addition, part of the resources will support the early preclinical phase of the TrkA-NAM project, which aims to innovate new pain management therapies. With the expert guidance of FNCA Sweden AB as its certified adviser, AlzeCure Pharma is poised to accelerate its progress, ensuring robust clinical investigations and potential future market entries. This investment not only underscores the investor community's confidence in the company’s vision and scientific approach but also reinforces AlzeCure Pharma’s commitment to making substantial advancements in neurological and pain therapeutics. For further details about these developments and the company’s groundbreaking work, interested parties are encouraged to visit the website at www.alzecurepharma.se or contact FNCA Sweden AB directly.
.png&w=3840&q=75)
